Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Fava

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Best Practice & Research. Clinical Haematology|December 5, 2009
Advances in the biology and therapy of patients with chronic myeloid leukaemiaElias Jabbour, Carmen Fava, Hagop Kantarjian
Haematologica|May 2, 2019
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?Giuseppe Saglio, Carmen Fava, Robert Peter Gale
Annals of Hematology|March 28, 2015
The choice of first-line chronic myelogenous leukemia treatmentCarmen Fava, Giovanna Rege-Cambrin, Giuseppe Saglio
Current Oncology Reports|July 24, 2012
Chronic myeloid leukemia: state of the art in 2012Carmen Fava, Giovanna Rege-Cambrin, Giuseppe Saglio
American Journal of Hematology|March 5, 2009
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemiaDushyant Verma, Carmen Fava, Hagop Kantarjian, et al.
Expert Opinion on Biological Therapy|January 7, 2014
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemiaAlessandro Morotti, Cristina Panuzzo, Carmen Fava, et al.
Drug Design, Development and Therapy|November 19, 2009
Development and targeted use of nilotinib in chronic myeloid leukemiaCarmen Fava, Hagop Kantarjian, Jorge Cortes, et al.
Clinical Lymphoma & Myeloma|December 17, 2009
Standard management of patients with chronic myeloid leukemiaCarmen Fava, Jorge E Cortés, Hagop Kantarjian, et al.
Expert Opinion on Emerging Drugs|April 1, 2015
Update on emerging treatments for chronic myeloid leukemiaCarmen Fava, Alessandro Morotti, Irene Dogliotti, et al.
International Journal of Molecular Sciences|October 26, 2024
Detection of <i>KIT</i> Mutations in Systemic Mastocytosis: How, When, and WhyDaniela Cilloni, Beatrice Maffeo, Arianna Savi, et al.
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Best Practice & Research. Clinical Haematology|December 5, 2009
Advances in the biology and therapy of patients with chronic myeloid leukaemiaElias Jabbour, Carmen Fava, Hagop Kantarjian
Haematologica|May 2, 2019
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?Giuseppe Saglio, Carmen Fava, Robert Peter Gale
Annals of Hematology|March 28, 2015
The choice of first-line chronic myelogenous leukemia treatmentCarmen Fava, Giovanna Rege-Cambrin, Giuseppe Saglio
Current Oncology Reports|July 24, 2012
Chronic myeloid leukemia: state of the art in 2012Carmen Fava, Giovanna Rege-Cambrin, Giuseppe Saglio
American Journal of Hematology|March 5, 2009
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemiaDushyant Verma, Carmen Fava, Hagop Kantarjian, et al.
Expert Opinion on Biological Therapy|January 7, 2014
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemiaAlessandro Morotti, Cristina Panuzzo, Carmen Fava, et al.
Drug Design, Development and Therapy|November 19, 2009
Development and targeted use of nilotinib in chronic myeloid leukemiaCarmen Fava, Hagop Kantarjian, Jorge Cortes, et al.
Clinical Lymphoma & Myeloma|December 17, 2009
Standard management of patients with chronic myeloid leukemiaCarmen Fava, Jorge E Cortés, Hagop Kantarjian, et al.
Expert Opinion on Emerging Drugs|April 1, 2015
Update on emerging treatments for chronic myeloid leukemiaCarmen Fava, Alessandro Morotti, Irene Dogliotti, et al.
International Journal of Molecular Sciences|October 26, 2024
Detection of <i>KIT</i> Mutations in Systemic Mastocytosis: How, When, and WhyDaniela Cilloni, Beatrice Maffeo, Arianna Savi, et al.
Pageof 12